semaglutide and heart disease Beyond obesity: Novo's SELECT re-defines cardiovascular risk management Recent study at UC Irvine

Providers typically recommend three primary injection sites for GLP-1 medications

As primary substrates for DPP-IV are GLP-1, GLP-2, and gastro-insulinotropic peptide (GIP), DPP-IV gene-deficient mice show improved postprandial glucose control and are resistant to progression of obesity and hyperinsulinemia (Drucker 2002

Together, we build a personalized treatment plan designed specifically for your body and physiology, not a one-size-fits-all treatment protocol

Despite the FDA's oversight of pharmaceutical marketing, the increasing popularity of GLP-1 agonists for weight loss has led to widespread off-label use, particularly as people seek alternatives to traditional weight loss medications

2026 AORN & ASA guidelines raise the bar for local anesthetic systemic toxicity preparedness at ASCs